FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileClinuvel Pharmaceuticals Ltd.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
CUVL
Clinuvel Pharmaceuticals Ltd. Stock AnalysisComprehensive stock analysis for Clinuvel Pharmaceuticals Ltd. (CUVL) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisCUVL
CUVL
Clinuvel Pharmaceuticals Ltd.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
CUVL
  1. Home
  2. Stocks
  3. Clinuvel Pharmaceuticals Ltd.
CU

Clinuvel Pharmaceuticals Ltd.

🇺🇸CUVL•NASDAQ
CU

Clinuvel Pharmaceuticals Ltd.

🇺🇸CUVL•NASDAQ
Market cap
$245.11M
P/E ratio
10.72

Your view on CUVL

Mkt Cap
$245.11M
P/E
10.72
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Clinuvel Pharmaceuticals Ltd.

Industry
Medical - Pharmaceuticals
Sector
Healthcare
CEO
Philippe Jacques Wolgen
Headquarters
535 Bourke Street, Melbourne, VIC, AU
Industry
Medical - Pharmaceuticals
Sector
Healthcare
CEO
Philippe Jacques Wolgen
Headquarters
535 Bourke Street, Melbourne, VIC, AU
Description

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.

Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide.

It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders.

In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Clinuvel Pharmaceuticals Ltd.. Starting points for Clinuvel Pharmaceuticals Ltd.: P/E 10.7, EPS $0.68, beta 0.57 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Clinuvel Pharmaceuticals Ltd.. Clinuvel Pharmaceuticals Ltd. paid $0.04 per share over the last year — a 0.7% yield at the current $4.86 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Clinuvel Pharmaceuticals Ltd.. Trailing twelve-month EPS for Clinuvel Pharmaceuticals Ltd. stands at $0.68. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Clinuvel Pharmaceuticals Ltd.. Clinuvel Pharmaceuticals Ltd. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold CUVL12 companies
More Medical - Pharmaceuticals companies
TickerTypeCompanySectorExchangeMkt cap
QMDTQuick-Med Technologies, Inc.HealthcareOTC$11,204
RADLYRaia Drogasil S.A.HealthcareOTC$8.8B
RBIIRising BioSciences, Inc.HealthcareOTC$4,991
RCDTFRecordati Industria Chimica e Farmaceutica S.p.A.HealthcareOTC$11.6B
RGEDFGedeon Richter PLCHealthcareOTC$5.7B
RLLVFRelevium Technologies Inc.HealthcareOTC$2.0M
RMRKRimrock Gold Corp.HealthcareOTC$234,228
ROTHPharmaRoth Labs, Inc.HealthcareOTC$35,118
RPGLFRegent Pacific Group LimitedHealthcareOTC$36.5M
RPRXRoyalty Pharma plcHealthcareNASDAQ$30.6B
RSCIRedwood Scientific Technologies, Inc.HealthcareOTC$1,872
RTEZRest Ez Inc.HealthcareOTC$1.9B
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Clinuvel Pharmaceuticals Ltd.. Coverage tracks Clinuvel Pharmaceuticals Ltd. within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Clinuvel Pharmaceuticals Ltd.

CUVL AnalysisWeak
Past
1
Growth
0
Health
5
Profit
0
Value
3